Compare ATYR & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | LFT |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 56.1M |
| IPO Year | N/A | N/A |
| Metric | ATYR | LFT |
|---|---|---|
| Price | $0.49 | $0.92 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 213.7K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 18.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $668.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.91 |
| 52 Week High | $7.29 | $2.45 |
| Indicator | ATYR | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 38.88 |
| Support Level | $0.43 | N/A |
| Resistance Level | $0.86 | $1.40 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.05 | 14.53 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.